Abstract

The present application relates to a tricyclic compound and use thereof as an MAT2A inhibitor.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07D 471/14 - Ortho-condensed systems
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.

IPC Classes  ?

• C07C 271/02 - Carbamic acidsSalts of carbamic acids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 31/325 - Carbamic acidsThiocarbamic acidsAnhydrides or salts thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07C 271/00 - Derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups

Abstract

Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

IPC Classes  ?

• C07D 271/10 - 1,3,4-OxadiazolesHydrogenated 1,3,4-oxadiazoles
• A61K 31/4245 - Oxadiazoles
• A61P 25/08 - AntiepilepticsAnticonvulsants

Abstract

The present invention relates to a parenteral liquid preparation containing, as active ingredients; a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof; and a cyclodextrin derivative.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/40 - CyclodextrinsDerivatives thereof

Abstract

The invention is directed to a method of treating attention-deficit/hyperactivity disorder (ADHD) in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07C 271/12 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine

Abstract

The present invention relates to a use for the purpose of preventing, alleviating, or treating status epilepticus by administering a medicament or pharmaceutical composition comprising a carbamate compound of chemical formula.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 25/08 - AntiepilepticsAnticonvulsants

Abstract

The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Abstract

The present disclosure includes the use of a miR-484 inhibitor for treating a disease or disorder associated with the increased level of miR-484. In some aspects, the miR-484 inhibitor is capable of reducing the expression of a gene and/or protein associated with miR-484.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/08 - AntiepilepticsAnticonvulsants

Abstract

The present disclosure relates generally to methods of treating autism spectrum disorders (ASD), using a compound of Formula (I).

IPC Classes  ?

• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the ox en atom.

IPC Classes  ?

• C07C 271/12 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine

Abstract

A seizure management system disclosed herein: detects seizure detection and prediction results from biological signals of a user by using a common seizure AI model that compares the similarity with a common seizure template composed of biological signals collected from a plurality of users secured in advance; accumulates user data, including the biological signals of the user and the seizure detection and prediction results, for a first period; updates the common seizure template and the common seizure AI model by using the accumulated user data; constructs a personal seizure AI model by using the accumulated user data; and selects a model optimized for the user from among the updated common seizure AI model or the personal seizure AI model.

IPC Classes  ?

• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G06N 3/0464 - Convolutional networks [CNN, ConvNet]
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/369 - Electroencephalography [EEG]
• A61B 5/318 - Heart-related electrical modalities, e.g. electrocardiography [ECG]
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb

Abstract

A method by which a computer detects and/or predicts an epileptic seizure on the basis of continuous biosignal measurement, according to one aspect of the present invention, comprises: a continuous complex biosignal measurement step in which a sensor unit receives complex biosignals including brain waves and a head electrocardiogram of a user, and the received biosignals including the brain waves and head electrocardiogram are preprocessed to be converted into digital signals; a step of extracting, from the biosignals of the user, characteristics of the biosignals including characteristics of the brain waves and characteristics of the head electrocardiogram; a step of inputting, into a machine learning algorithm, the extracted characteristics of the biosignals including characteristics of the brain waves and characteristics of the head electrocardiogram, and analyzing same; and a step of storing or outputting seizure detection and/or prediction results according to the analysis results.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/372 - Analysis of electroencephalograms
• A61B 5/346 - Analysis of electrocardiograms
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present application relates to a novel tricyclic derivative compound as a KRAS G12D inhibitor, and a use thereof. The compound according to one embodiment of the present application inhibits the activity of a KRAS G12D mutant protein, and thus can be used in the prevention or treatment of diseases caused by a KRAS G12D mutation.

IPC Classes  ?

• C07D 487/08 - Bridged systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• C07D 487/04 - Ortho-condensed systems
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Abstract

The present disclosure pertains to a pharmaceutical combination for treating and/or preventing cancer and a method and use thereof. Specifically, the present disclosure involves a method for inhibiting tumor growth by combining a substance inhibitory of the activity of protein arginine methyltransferase and a drug that is similar to or different from the substance in terms of mechanism, and/or a pharmaceutical combination useful for reducing tumor volume using same. Particularly, a pharmaceutical combination comprising a PRMT5 inhibitor and a DNA damage-inducing substance is provided.

IPC Classes  ?

• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure provides a compound of a specific chemical structure, an optical isomer, stereoisomer, isotopic variant, hydrate or solvate thereof, or a pharmaceutically acceptable salt thereof, which has excellent activity in terms of degradation of SHP2 protein. The present disclosure also provides a composition comprising such a compound, an optical isomer, stereoisomer, isotopic variant, hydrate or solvate thereof, or a pharmaceutically acceptable salt thereof. The present disclosure also provides medical uses of a composition comprising the compound according to the present disclosure, an optical isomer, stereoisomer, isotopic variant, hydrate or solvate thereof, or a pharmaceutically acceptable salt thereof, for the treatment or prevention of SHP2-associated diseases (for example, cancer). The present disclosure also provides a method for treating or preventing SHP2-associated diseases (for example, cancer), the method comprising administering, to an individual in need of treatment, an effective amount of a composition comprising the compound according to the present disclosure, an optical isomer, stereoisomer, isotopic variant, hydrate or solvate thereof, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 471/10 - Spiro-condensed systems

Abstract

The present disclosure relates to a compound derivative containing a 6-7 bicyclic ring and use thereof. The compound according to the present invention can be effectively used in the prevention or treatment of diseases caused by PRMT5 by acting as a PRMT5 inhibitor.

IPC Classes  ?

• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 491/08 - Bridged systems
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.

IPC Classes  ?

• A61K 31/325 - Carbamic acidsThiocarbamic acidsAnhydrides or salts thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07C 271/00 - Derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups
• C07C 271/02 - Carbamic acidsSalts of carbamic acids

Abstract

A wearable device comprises a sensor unit and a control unit. The sensor unit: includes a plurality of electrodes which are mounted on the head of a user above the cervical portion and acquire electrical signals from the head; acquires an electroencephalogram of the user on the basis of the difference between the electronic signals acquired by two of the plurality of electrodes; and acquires an electrocardiogram of the user on the basis of the difference between the electrical signals acquired by two other electrodes among the plurality of electrodes. The control unit is electrically connected with the sensor unit, and converts, into digital signals, the analog signals of the electroencephalogram and electrocardiogram acquired by the sensor unit.

IPC Classes  ?

• A61B 5/256 - Wearable electrodes, e.g. having straps or bands
• A61B 5/28 - Bioelectric electrodes therefor specially adapted for particular uses for electrocardiography [ECG]
• A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/266 - Bioelectric electrodes therefor characterised by the electrode materials containing electrolytes, conductive gels or pastes

Abstract

A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.

IPC Classes  ?

• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings

Abstract

The present disclosure provides a compound represented by Formula (I) or a pharmaceutically acceptable salt which are effective as a sodium channel blocker and a method of using the compound.

IPC Classes  ?

• C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

The present application relates to a solid oral preparation and a preparation method therefor, the preparation comprising granules, which comprise: as an active ingredient, a carbamate compound of chemical formula 1, or a pharmaceutically acceptable salt, an isomer, solvate or a hydrate thereof; a diluent; and a binder.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

Abstract

The present invention relates to a blend for prevention, mitigation, or treatment of schizophrenia, the blend containing a carbamate compound of chemical formula 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and, more specifically, to a blend and a pharmaceutical composition each containing a carbamate compound of chemical formula 1 and aripiprazole, and to a use thereof for treating schizophrenia.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Abstract

The present disclosure provides combination therapy using [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate (cenobamate) and one or more antiepileptic drugs for the prevention or treatment of a neurological disorder such as epilepsy.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/515 - Barbituric acidsDerivatives thereof, e.g. sodium pentobarbital
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Abstract

The present disclosure relates to a compound derivative containing a 6-7 bicyclic ring and use thereof. The compound according to the present disclosure can be effectively used in the prevention or treatment of diseases caused by PRMT5 by acting as a PRMT5 inhibitor.

IPC Classes  ?

• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 491/08 - Bridged systems
• C07D 487/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents

Abstract

The invention is directed to a method of treating attention-deficit/hyperactivity disorder (ADHD) in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07C 271/12 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine

Abstract

The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.

IPC Classes  ?

• C07C 275/60 - Y being an oxygen atom, e.g. allophanic acids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/26 - Psychostimulants, e.g. nicotine, cocaine

Abstract

The present invention relates to a newly identified solvate form of (R)-2-amino-3-phenylpropyl carbamate (APC) hydrochloride, a method of preparing APC hydrochloride, and methods of using the same to treat disorders. The invention further relates to methods of producing APC hydrochloride with increased purity.

IPC Classes  ?

• C07C 271/12 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 25/24 - Antidepressants

Abstract

The present invention relates to a method for treating or preventing obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. The invention further relates to methods for reducing body weight and/or reducing food intake in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.

IPC Classes  ?

• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate

Abstract

The present invention relates to an oral pharmaceutical composition comprising a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof as an active ingredient, and a preparation method therefor.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

Abstract

Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

IPC Classes  ?

• C07D 271/10 - 1,3,4-OxadiazolesHydrogenated 1,3,4-oxadiazoles
• A61K 31/4245 - Oxadiazoles
• A61P 25/08 - AntiepilepticsAnticonvulsants

Goods & Services

(1) Medicines for human purposes and veterinary preparations for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; dietetic foods adapted for medical purposes for the prevention and treatment of iron deficiency and anaemia in humans; dietetic food adapted for veterinary use for the prevention and treatment of iron deficiency and anaemia in animals; dietetic substances adapted for medical use, namely sugar substitutes adapted for medical purposes; dietetic substances adapted for veterinary use consisting of vitamins, minerals, amino acids and trace elements; chemical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, urinary tract infections, respiratory infections, eye infections, infections of the spinal cord; biological preparations for medical purposes, namely for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; biochemical preparations for medical purposes, namely for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; chemicals for pharmaceutical use, namely for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; food supplements consisting of trace elements; dietetic substances consisting of trace elements; ferments for pharmaceutical purposes for use as pharmaceutical preparations for general health and well-being; biotechnological preparations for medical purposes, namely for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; blood solvent, namely blood plasma, albumin, globulin, fibrinogen, thrombocyte and platelets; chemical preparations for medicinal purposes, namely for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; chemical preparations for medical or veterinary purposes, namely for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; immunomodulators; vitamin preparations; human vaccines; dietary supplements, namely bee pollen, acai powder, albumin, amino acid, casein, dietary fiber; dietary supplements for general health and well-being; therapeutic drugs and agents for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; chemico-pharmaceutical preparations for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; bacteriological preparations for medical and veterinary use for acetification

Abstract

The present invention relates to a 6-6 bicyclic ring-containing compound derivative and use thereof. The compound according to the present invention acts as a PRMT5 inhibitor, and thus can be effectively used in the prevention or treatment of diseases caused by PRMT5.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/08 - Bridged systems
• C07D 491/08 - Bridged systems
• C07D 471/04 - Ortho-condensed systems
• C07D 498/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to an aqueous formulation comprising as an active ingredient a carbamate compound of Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, poloxamer, and an aqueous carrier, wherein the aqueous formulation is in the form of a suspension formulation.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 9/10 - DispersionsEmulsions
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to an oral pharmaceutical composition comprising a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof as an active ingredient, and a preparation method therefor.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 9/20 - Pills, lozenges or tablets

Abstract

The present disclosure relates to a compound derivative containing a 6-7 bicyclic ring and use thereof. The compound according to the present invention can be effectively used in the prevention or treatment of diseases caused by PRMT5 by acting as a PRMT5 inhibitor.

IPC Classes  ?

• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 491/08 - Bridged systems
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

The present disclosure relates generally to methods of treating autism spectrum disorders (ASD), using a compound of Formula (I).

IPC Classes  ?

• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia

Abstract

The present invention relates to a use, for the prevention, alleviation or treatment of developmental disability, of an imidazopyrimidine or imidazotriazine compound of chemical formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

IPC Classes  ?

• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61P 25/16 - Anti-Parkinson drugs
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present disclosure relates to an aqueous formulation comprising as an active ingredient a carbamate compound of Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, poloxamer, and an aqueous carrier, wherein the aqueous formulation is in the form of a suspension formulation.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsEmulsions
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present disclosure relates to an aqueous formulation comprising as an active ingredient a carbamate compound of Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, poloxamer, and an aqueous carrier, wherein the aqueous formulation is in the form of a suspension formulation.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsEmulsions
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/02 - Inorganic compounds
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to a use of imidazopyrimidine or imidazotriazine compounds of Chemical Formula 1, or pharmaceutically acceptable salts, solvates, or hydrates thereof, for preventing, alleviating or treating cognitive disorder or for improving enhancing cognitive function.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Abstract

The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating myotonia.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to a use of a pharmaceutical composition comprising the carbamate compound of chemical formula 1 in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder by administering the pharmaceutical composition.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61P 25/22 - Anxiolytics

Abstract

The present disclosure relates to a method for preparing aryl 2-tetrazol-2-yl ketone of the following Formula 1a with improved selectivity: The present disclosure relates to a method for preparing aryl 2-tetrazol-2-yl ketone of the following Formula 1a with improved selectivity: wherein R1 and R2 are the same as defined herein.

IPC Classes  ?

• C07D 257/04 - Five-membered rings

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating trigeminal neuralgia, the pharmaceutical composition comprising: a carbamate compound of chemical formula 1 or a pharmaceutically acceptable salt thereof, a solvate or a hydrate; and a pharmaceutically acceptable carrier. The pharmaceutical composition, according to the present invention, may enable the efficient prevention or treatment of trigeminal neuralgia.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

The present application relates to a solid oral preparation and a preparation method therefor, the preparation comprising granules, which comprise: as an active ingredient, a carbamate compound of chemical formula 1, or a pharmaceutically acceptable salt, an isomer solvate or a hydrate thereof; a diluent; and a binder.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present application relates to a solid oral preparation and a preparation method therefor, the preparation comprising granules, which comprise: as an active ingredient, a carbamate compound of chemical formula 1, or a pharmaceutically acceptable salt, an isomer solvate or a hydrate thereof; a diluent; and a binder.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

IPC Classes  ?

• C07D 271/10 - 1,3,4-OxadiazolesHydrogenated 1,3,4-oxadiazoles
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61K 31/4245 - Oxadiazoles

Abstract

The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.

IPC Classes  ?

• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 31/325 - Carbamic acidsThiocarbamic acidsAnhydrides or salts thereof
• C07C 271/02 - Carbamic acidsSalts of carbamic acids
• C07C 271/00 - Derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/20 - Pills, lozenges or tablets

Abstract

The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating myotonia.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to a use to be used for the purpose of preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy by administering a pharmaceutical composition containing a carbamate compound of chemical formula 1.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids

Abstract

The present invention relates to a blend for prevention, mitigation, or treatment of schizophrenia, the blend containing a carbamate compound of chemical formula 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and, more specifically, to a blend and a pharmaceutical composition each containing a carbamate compound of chemical formula 1 and aripiprazole, and to a use thereof for treating schizophrenia.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Abstract

The present invention relates to a use for the purpose of preventing, alleviating, or treating status epilepticus by administering a medicament or pharmaceutical composition comprising a carbamate compound of chemical formula 1.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 25/08 - AntiepilepticsAnticonvulsants

Abstract

The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: 2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Goods & Services

Medical information; providing healthcare and medical information; providing medical information, consultancy and advisory services; providing medical information in the field of brain diseases prevention, screening, diagnosis and treatment; providing medical information in the field of neuro-degenerative brain disease; providing medical information via a web site; providing medical information in the field of brain disease prevention, treatment and cures via a web site; medical and pharmaceutical consultation; medical and pharmaceutical consultation relating to brain diseases; Health assessment services, specifically, conducting health assessment surveys; health assessment services related to the responses to a health status survey; Health assessment services, specifically, conducting health assessment surveys in the field of brain diseases, namely, conducting health assessment survey questionnaires in the field of brain diseases; health assessment services, namely, conducting health risk assessment surveys and health screening in the field of brain diseases; Conducting medical information surveys as being the medical diagnosis and treatment of brain diseases, namely, conducting surveys of patients with brain diseases; medical analysis services relating to the treatment of patients; medical analysis services for diagnosis, prognosis, ascertaining of medical symptoms and treatment of persons with brain diseases; medical analysis services for diagnostic and medical treatment purposes; medical reporting services being health assessment services, namely, compilation of medical reports; medical reporting services being health assessment services, namely, preparation of reports relating to health care matters; medical reporting services being health assessment services, namely, reporting of responses to a health status survey; Health assessment services, namely, providing an online searchable database in the field of brain disease information based on collected data and information, all for treatment and diagnostic purposes; providing an internet-based database of patient medical information where patients can inquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community; medical diagnostic testing, monitoring and reporting services, namely, conducting a web based medical survey especially in the field of brain diseases and for the preparation of reports relating to the symptoms and care of individuals; providing online health care information in the nature of surveys, reports, research papers, legislative analysis, and forecasts in the field of health care and brain diseases

Abstract

The present invention relates to an oral pharmaceutical composition comprising a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof as an active ingredient, and a preparation method therefor.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 25/08 - AntiepilepticsAnticonvulsants

Abstract

The present invention relates to an oral pharmaceutical composition comprising a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof as an active ingredient, and a preparation method therefor.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 25/08 - AntiepilepticsAnticonvulsants

Abstract

The present disclosure relates to a method for preparing aryl 2-tetrazol-2-yl ketone of Formula la with improved selectivity:

IPC Classes  ?

• C07D 257/04 - Five-membered rings

Abstract

The present disclosure relates to a method for preparing aryl 2-tetrazol-2-yl ketone of the following Formula 1a with improved selectivity: 2 are the same as defined herein.

IPC Classes  ?

• C07D 257/04 - Five-membered rings

Abstract

The present invention relates to a use of imidazopyrimidine or imidazotriazine compounds of chemical formula 1, or pharmaceutically acceptable salts, solvates, or hydrates thereof, for preventing, alleviating, or treating cognitive disorders or for improving cognitive function.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/131 - Amines, e.g. amantadine acyclic
• A61K 31/4458 - Non-condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 487/04 - Ortho-condensed systems

Abstract

The present invention relates to a use, for the prevention, alleviation, or treatment of developmental disability, of an imidazopyrimidine or imidazotriazine compound of chemical formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/00 - Drugs for disorders of the nervous system
• C07D 487/04 - Ortho-condensed systems

Abstract

The present invention relates to a 6-6 bicyclic ring-containing compound derivative and use thereof. The compound according to the present invention acts as a PRMT5 inhibitor, and thus can be effectively used in the prevention or treatment of diseases caused by PRMT5.

IPC Classes  ?

• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 35/00 - Antineoplastic agents
• A61P 7/06 - Antianaemics
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present disclosure relates to a method for preparing aryl 2-tetrazol-2-yl ketone of Formula 1a with improved selectivity.

IPC Classes  ?

• C07D 257/04 - Five-membered rings

Abstract

The present invention relates to a 6-6 bicyclic ring-containing compound derivative and use thereof. The compound according to the present invention acts as a PRMT5 inhibitor, and thus can be effectively used in the prevention or treatment of diseases caused by PRMT5.

IPC Classes  ?

• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 7/06 - Antianaemics
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The present invention relates to a use, for the prevention, alleviation, or treatment of developmental disability, of an imidazopyrimidine or imidazotriazine compound of chemical formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 487/04 - Ortho-condensed systems

Abstract

The present invention relates to a use of imidazopyrimidine or imidazotriazine compounds of chemical formula 1, or pharmaceutically acceptable salts, solvates, or hydrates thereof, for preventing, alleviating, or treating cognitive disorders or for improving cognitive function.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 487/04 - Ortho-condensed systems

Abstract

Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

IPC Classes  ?

• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• C07D 271/10 - 1,3,4-OxadiazolesHydrogenated 1,3,4-oxadiazoles
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61K 31/4245 - Oxadiazoles

Abstract

The present disclosure relates to a compound derivative containing a 6-7 bicyclic ring and use thereof. The compound according to the present invention can be effectively used in the prevention or treatment of diseases caused by PRMT5 by acting as a PRMT5 inhibitor.

IPC Classes  ?

• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 491/08 - Bridged systems
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

The present invention relates to a compound derivative bearing a 6-7 bicyclic ring and a use thereof. The compound according to the present invention acts as a protein arginine methyltransferases 5 (PRMT5) inhibitor and thus can be advantageously used to prevent or treat a disease caused by PRMT5.

IPC Classes  ?

• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A61P 35/00 - Antineoplastic agents
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to a compound derivative bearing a 6-7 bicyclic ring and a use thereof. The compound according to the present invention acts as a protein arginine methyltransferases 5 (PRMT5) inhibitor and thus can be advantageously used to prevent or treat a disease caused by PRMT5.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

The present invention relates to an orally disintegrated tablet and a method for producing same, the tablet containing a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof, as an active ingredient.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the ox en atom.

IPC Classes  ?

• C07C 271/12 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to a method for treating or preventing obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. The invention further relates to methods for reducing body weight and/or reducing food intake in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.

IPC Classes  ?

• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate

Abstract

The invention is directed to a method of treating attention-deficit/hyperactivity disorder (ADHD) in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07C 271/12 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine

Abstract

The present invention relates to a newly identified solvate form of (R)-2-amino-3-phenylpropyl carbamate (APC) hydrochloride, a method of preparing APC hydrochloride, and methods of using the same to treat disorders. The invention further relates to methods of producing APC hydrochloride with increased purity.

IPC Classes  ?

• C07C 271/12 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 25/24 - Antidepressants
• C07C 269/08 - SeparationPurificationStabilisationUse of additives

Goods & Services

Pharmaceutical and veterinary preparations; pharmaceuticals; chemical preparations for pharmaceutical purposes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the prevention of disorders of the nervous system; psychotropics; soporifics; pain relief preparations; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for the treatment of multiple sclerosis; medicated preparations for skin treatment; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for preventing and treating seizure; pharmaceutical preparations for the treatment of cardiovascular disease; pills for dizziness symptoms treatment; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical products for treating respiratory diseases.

Abstract

The present disclosure provides combination therapy using [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate (cenobamate) and one or more antiepileptic drugs for the prevention or treatment of a neurological disorder such as epilepsy.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/515 - Barbituric acidsDerivatives thereof, e.g. sodium pentobarbital
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Goods & Services

Pharmaceutical and veterinary preparations; pharmaceuticals; chemical preparations for pharmaceutical purposes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the prevention of disorders of the nervous system; psychotropics; soporifics; pain relief preparations; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for the treatment of multiple sclerosis; medicated preparations for skin treatment; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for preventing and treating seizure; pharmaceutical preparations for the treatment of cardiovascular disease; pills for dizziness symptoms treatment; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical products for treating respiratory diseases.

Abstract

The present invention relates to use of a carbonate compound of chemical formula 1, or a pharmaceutically permissible salt, solvate or hydrate thereof, for prevention, alleviation or treatment of visceralgia, or pain arising from visceral disease.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 25/08 - AntiepilepticsAnticonvulsants

Abstract

The present invention relates to a use of a carbamate compound of formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof in the prevention or treatment of diseases associated with an increase in late sodium current.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 9/00 - Medicinal preparations characterised by special physical form

Goods & Services

Pharmaceutical preparations for the treatment of epilepsy; pharmaceutical products for the treatment of epilepsy; chemical preparations for pharmaceutical purposes for the treatment and relief of epilepsy; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for the prevention of disorders of the nervous system; psychotropics; soporifics; pain relief preparations; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for the treatment of multiple sclerosis; medicated preparations for treating skin disorders; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for preventing and treating seizure; pharmaceutical preparations for the treatment of cardiovascular disease; pills for treating symptoms of dizziness; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical products for treating respiratory diseases

Goods & Services

(1) Pharmaceuticals for the treatment of epilepsy; chemical preparations for pharmaceutical purposes, namely for the treatment of epilepsy; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; psychotropics; soporifics; pain relief preparations; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for preventing and treating seizure; pharmaceutical preparations for the treatment of cardiovascular disease; pills for dizziness symptoms treatment; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical products for treating respiratory diseases

Goods & Services

Pharmaceutical and veterinary preparations; pharmaceuticals; chemical preparations for pharmaceutical purposes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the prevention of disorders of the nervous system; psychotropics; soporifics; pain relief preparations; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for the treatment of multiple sclerosis; medicated preparations for skin treatment; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for preventing and treating seizure; pharmaceutical preparations for the treatment of cardiovascular disease; pills for dizziness symptoms treatment; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical products for treating respiratory diseases.

Abstract

The present invention relates to a blend for prevention, mitigation, or treatment of schizophrenia, the blend containing a carbamate compound of chemical formula 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and, more specifically, to a blend and a pharmaceutical composition each containing a carbamate compound of chemical formula 1 and aripiprazole, and to a use thereof for treating schizophrenia.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Abstract

The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: 2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Abstract

The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for reducing or treating developmental disorders including fragile X syndrome, Angelman syndrome or Rett syndrome.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 25/00 - Drugs for disorders of the nervous system

Goods & Services

Medical services in the field of epilepsy; providing medical information in the field of epilepsy prevention, screening, diagnosis and treatment; medical and pharmaceutical consultation relating to epilepsy; providing medical information in the field of epilepsy; medical information services in the field of epilepsy provided via the Internet ; medical consultancy for selecting appropriate medicines; health assessment services, namely, providing a database in the field of epilepsy information based on collected data; health care services, namely, providing a database in the field of epilepsy information based on collected data and information, all for treatment and diagnostic purposes; analysis of health information and data relating to epilepsy for medical diagnostic and medical treatment purposes; conducting medical information surveys in the field of epilepsy, namely, conducting health surveys of patients with epilepsy for medical purposes; Health assessment services, namely, conducting health assessment survey in the field of epilepsy consisting of a series of health-related questions for response from the user; providing medical information to patients and medical professionals in the form of reports in the field of epilepsy; medical analysis services for diagnosis, prognosis, ascertaining of medical symptoms and treatment of persons with epilepsy; medical analysis services to facilitate the assessment of patient conditions and the development of personalized treatment protocols for patients with epilepsy; providing medical information and information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals in the field of epilepsy based on survey results; providing a web site featuring medical information; health care services, namely, disease management programs; medical information; health assessment services related to the responses to a health status survey; medical reporting of responses to a health status survey; providing medical information about epilepsy and its conditions, symptoms, detection, prevention and treatment, and medical information on patient health and experiences; Providing an internet-based database of patient medical information where patients can inquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community; Providing a series of health-related questions for response from the user for conducting self-assessments in the field of physical and mental health, featuring questions about access to health care services, health care costs, and access to food, housing and utilities, and personal independence, and compiling data related to all of the foregoing all for medical diagnostic or medical treatment purposes; Medical analysis services for diagnostic and medical treatment purposes

Abstract

The present invention relates to a use to be used for the purpose of preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy by administering a pharmaceutical composition containing a carbamate compound of chemical formula 1.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

The present invention relates to a use to be used for the purpose of preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy by administering a pharmaceutical composition containing a carbamate compound of chemical formula 1.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

The present disclosure relates to a method for preparing aryl 2-tetrazol-2-yl ketone of the following Formula 1a with improved selectivity: 2 are the same as defined herein.

IPC Classes  ?

• C07D 257/04 - Five-membered rings

Abstract

The present invention relates to a use of a pharmaceutical composition comprising the carbamate compound of chemical formula 1 in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder by administering the pharmaceutical composition.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Disclosed in the present invention is an oxadiazole compound and pharmaceutically useful salts thereof. The compound and pharmaceutically useful salts thereof are especially suitable for the treatment of nervous system diseases such as epilepsy.

IPC Classes  ?

• C07D 271/10 - 1,3,4-OxadiazolesHydrogenated 1,3,4-oxadiazoles
• A61K 31/4245 - Oxadiazoles
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Disclosed in the present invention is an oxadiazole compound and pharmaceutically useful salts thereof. The compound and pharmaceutically useful salts thereof are especially suitable for the treatment of nervous system diseases such as epilepsy.

IPC Classes  ?

• C07D 271/10 - 1,3,4-OxadiazolesHydrogenated 1,3,4-oxadiazoles
• A61K 31/4245 - Oxadiazoles
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to a use for the purpose of preventing, alleviating, or treating concurrent seizures by administering a medicament or pharmaceutical composition comprising a carbamate compound of chemical formula 1.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a use of a pharmaceutical composition comprising the carbamate compound of chemical formula 1 in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder by administering the pharmaceutical composition.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to a use for the purpose of preventing, alleviating, or treating concurrent seizures by administering a medicament or pharmaceutical composition comprising a carbamate compound of chemical formula 1.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents

Goods & Services

Immunomodulators; vaccines; vitamin preparations; preparations of trace elements for human and animal use; dietary supplements; dietetic food supplements, namely, dietetic foods adapted for medical purposes, dietetic food adapted for veterinary use, dietetic substances adapted for medical use, dietetic substances adapted for veterinary use; chemicals for pharmaceutical use; ferments for pharmaceutical purposes; chemico-pharmaceutical preparations; chemical preparations for sanitary use; chemical preparations for medical or veterinary purposes; bacteriological preparations for medical and veterinary use; biotechnological preparations for medical purposes; biological preparations for medical purposes; biochemical preparations for medical purposes; sanitary preparations for medical purposes; chemical preparations for medicinal purposes; medicines for human purposes and veterinary preparations; therapeutic drugs and agents; clinical medical reagents for processing human whole blood and its components for use in blood transfusions stored in bags, bottles, syringes and other such containers used to store such substances in the medical field.

Abstract

The present invention relates to a use for preventing, alleviating or treating pruritus by administering a pharmaceutical composition comprising a carbamate compound of following Formula 1.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 17/04 - Antipruritics

Abstract

The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: 4 is H— or aryl.

IPC Classes  ?

• A61K 31/325 - Carbamic acidsThiocarbamic acidsAnhydrides or salts thereof
• C07C 275/60 - Y being an oxygen atom, e.g. allophanic acids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Goods & Services

(1) Immunomodulators; human vaccines; vitamin preparations; preparations of trace elements for human and animal use; dietary supplements, namely bee pollen, acai powder, albumin, amino acid, casein, dietary fiber; dietary supplements for general health and well-being; dietetic food supplements, namely, dietetic foods adapted for medical purposes for the prevention and treatment of iron deficiency and anaemia in humans; dietetic food adapted for veterinary use for the prevention and treatment of iron deficiency and anaemia in animals; dietetic substances adapted for medical use, namely sugar substitutes adapted for medical purposes; dietetic substances adapted for veterinary use consisting of vitamins, minerals, amino acids and trace elements; chemicals for pharmaceutical use, namely for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; ferments for pharmaceutical purposes for use as pharmaceutical preparations for general health and well-being; chemico-pharmaceutical preparations for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; chemical preparations for sanitary use, namely nasal cleaning preparations; chemical preparations for medical or veterinary purposes, namely for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; bacteriological preparations for medical and veterinary use for acetification; biotechnological preparations for medical purposes, namely for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; biological preparations for medical purposes, namely for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; biochemical preparations for medical purposes, namely for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; sanitary preparations for medical purposes for use for preventing pathogenic infections in humans and animals; chemical preparations for medicinal purposes, namely for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; medicines for human purposes and veterinary preparations for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; therapeutic drugs and agents for the treatment of central nervous system diseases, epilepsy, cancer and metabolic diseases; clinical medical reagents for processing human whole blood and its components for use in blood transfusions stored in bags, bottles, syringes and other such containers used to store such substances in the medical field.